Original Articles
Published May 13, 2020
Article Tools
DOI
Article Level Metrics
Share this article
facebook twitter linkedin

Keywords

White Blood Count
Systolic Heart Failure
Congestive Heart Failure

How to Cite

pazoki, hamraz, Amirfarhangi, A., & Salehabadi, G. (2020). Evaluating the prognosis value of White Blood Count (WBC) count in Congestive Heart Failure (CHF). Internal Medicine and Medical Investigation Journal, 5(1). https://doi.org/10.24200/imminv.v5i1.256

Evaluating the prognosis value of White Blood Count (WBC) count in Congestive Heart Failure (CHF)

hamraz pazoki
Medical Doctor, Tehran University of Medical Sciences, Tehran, Iran
Abdollah Amirfarhangi
Cardiology department, Iran University of Medical Sciences, Tehran, Iran
Ghazaleh Salehabadi
Student Research Committee, School of Medicine, Iran University of Medical Sciences, Tehran, Iran

Introduction: Congestive heart failure (CHF) is a condition of heart muscle weakness and ventricular dysfunction that leads to fatigue and dyspnea. Currently more than 5 million people are suffering from CHF worldwide. CHF includes wide range of symptoms and has different prognosis and treatments. There are so many prognostic factors for identifying high risk patients (such as age, left ventricular dysfunction and etc.) but lately researchers  have focused on some new factors such as inflammatory markers, natriuretic peptide and leukocytosis. So in this study we aimed to evaluate prognostic effects of CBC findings  specially WBC on prognosis of CHF during hospitalization and 6 months after discharge in CHF patients.

Method and materials:  This retrospectitive cohort study was done in Rasoul Akram Hospital of Tehran September 2017 until September 2019. Information such as demographic ones (age and gender), CBC (WBC, HB, Platelets), blood sugar, TG & cholesterol, sodium and potassium in the first test after hospitalization were derived from the files and recorded in a standard check list.

The inclusion criteria consisted of age above 18 and the absolute diagnose of CHF. The exclusion criteria were trauma, surgery or co morbidities such as diabetes mellitus and hypertension. complications during hospitalization were defined as death in the hospital or hospitalization more than 5 days. Complications after 6 months of discharge were defined as death, readmitting to the hospital because of MI, Angina or heart attack and Need a kind of mechanical therapy such as pace maker. Statistical analyses were performed using Statistical software SPSS version 22.  Statistical significance was considered at p < 0.05.

Results: 117 patients consisted of 53 women (45.3%) and 64 men (54.7%) were included in the study. The means and SD of age was 70±14. 65 patients (55.6%) of 117 ones suffered from hypertension and 48 patients (41%) had diabetes mellitus.

The means and SD of hemoglobin and hematocrit of patients were 11.6±2.1 and 36.1±6.,the amount of WBC, hemoglobin, hematocrites and platelets has no significant differences (P value>0.05) between short term and long term events.

Discussion: findings show that patients suffered from mild to moderate anemia. As shown in the previous studies, anemia is a common co morbidity with CHF. Anemia causes an increase in cardiac output, sympathetic activity, extracellular fluid and plasma. It worsens the symptoms, cause re hospitalization and increase in hospitalization period and treatment costs. Finally it causes CHF prognosis to get worse.

Some previous studies showed that low hemoglobin and hematocrit cause an increase in death within 30 days in AMI and ACS but findings of this study showed that there is no correlation between WBC count and CHF outcomes. Because of contradictory findings it seems necessary that more studies with huge samples be conducted.

Conclusion: WBC count has no correlation with CHF outcomes and it can not be used as a prognostic value.

Key words: WBC count- systolic heart failure- CHF

https://doi.org/10.24200/imminv.v5i1.256

References

Elahi M, Mahmoud M, Shahbaz A. et al. Current concepts underlying benefits of exercise training in congestive heart failure patients. Curr Cardiol Rev. 2010;6(2):104-11

Romanovsky A, Bagshaw S, Rosner MH. Hyponatremia and Congestive heart failure: A marker of increased mortality and a target for therapy. Int J Nephrol. 2011;2011:732746

Pesaro AE, Nicolau JC, Serrano CV Jr, et al. Influence of leukocytes and glycemia on the prognosis of patients with acute myocardial infarction. 2009; 92(2):84-93.

Zhang L, Zalewski A, Liu Y, et al., Diabetes-induced oxidative stress and low grade inflammation porcine coronary arteries. Circulation. 2003; 108: 472-8.

Patel MR. Mahaffey KW,. Armstrong PW, et al. Prognostic usefulness of white blood cell count and temperature in acute myocardial infarction, (from the CARDINAL Trial), Am J Cardiol. 2005: 95:614-8.

Braunwald E. Heart Disease Textbook. 6th ed. Philadelphia: Saunders; 1998.

Mak G, Murphy NF, McDonald K. Anemia in heart failure: to treat or not to treat? Curt at Options Cardiovasc Med 2008; 10(6):455-64.

Horwich TB, Fonarow GC. Hamilton MA, MacLellan WR, Borenstein J. Anemia is associated with worse symptoms, greater impairment in function capacity and a significant increase in mortality in patients with advanced heart failure. J Am Coll Cardiol 2002;39: 1780-86.

Miklik R., Parenica J , Spinar J. The prevalence of anemia and its impact on hospitalization mortality in patients with acute heart failure. Vnitr Lek 2010;56(5)382-91.

Hamaguchi S, Tsuchihashi-Makaya M, Kinugawa S, Yokota T, Takeshita A. Yokoshiki H, et al. The JCARE-CARD Investigators. Anemia is an Independent Predictor of Long-Term Adverse Outcomes in Patients Hospitalized with Heart Failure in Japan. Circ J. 2009; 12(4) 12-22. 28.

Tehrani F, Phan A, Morrissey R., Chien C. Rafique A, Schwarz E. The Prognostic Value of Anemia in Patients with Diastolic Heart Failure. TeX Heart Inst J 2009; 36(3):220-5.

Tang WH, Tong W. Jain A, Francis GS, Harris CM, Young JB. Evaluation and long term prognosis of new-onset and transient, and persistant anemia in ambulatory patients with chronic heart failure. J Am Coll Cardiol200851(5):577-80

Marchioli R. Avanzini F, Barzi F, et al. G1SSI-prevenzione investigators, assessment of absolute risk of death after myocardial infarction by use of multiple-risk-factor assessment questionare: GISSI-prevenzione mortality risk chart. Eur Heart J. 2001;22:2085-103

Barron HV. Harr SD, Radford M.J, et al. The association between white blood cell count and acute myocardial infarction mortality in patients N or =65 years age: findings from the cooperative cardiovascular project. J Am Coll Cardiol 2001;38:165-1-61.

Grzybowski M, Welch RD, Parsons L, et al. The association between white blood cell count and acute myocardial infarction in-hospital mortality: findings from the National Registry of Myocardial Infarction. Acad Emerg Med 2004;11:1049-60

Menon V, Lessard D, Yarzebski J, et al. Leukocytosis and adverse hospital outcomes after acute myocardial infarction. Am J Cardiol 2003;92:368-72.

Sjauw KD, van der Hourst IC, Nijsten MW, et al. Value of routine admission laboratory tests to predict thirty-day mortality in patients with acute myocardial infarction. Am J Cardiol 2006;97: 1435-40.

Eikelboom JW, Anand SS, Mehta SR, et al. Prognostic significance of thrombocytopenia during hirudin and heparin therapy in acute coronary syndrome without ST elevation: Organization to Assess Strategies for Ischemic Syndromes (OASIS-2) study. Circulation 2001; 103:643-50.

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.